TPI-1917-49
TPI-1917-49 is an agent that can cross the blood-brain barrier and reduce amyloid β (Aβ) . TPI-1917-49 reduces the production of Aβ peptide segments by promoting the non-amyloidogenic pathway of amyloid precursor protein (APP) (increasing the generation of sAPPα mediated by α-secretase) . TPI-1917-49 reduces amyloid plaques in mouse models. TPI-1917-49 can be used in Alzheimer's disease research[1].
Product Specifications
CAS Number
1250849-11-6
UNSPSC
12352005
Target
Amyloid-β
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Smiles
O=C(C1=CC=C(C(NC2=NC(C3=CC=CC(O)=C3)=CS2)=C1)N4CCN(CC4)C5=NC(C6=CC=CC(O)=C6)=CS5)N
Molecular Formula
C29H26N6O3S2
Molecular Weight
570.69
References & Citations
[1]Wang H, et al. Substituted dithiazole piperazine benzamides as novel amyloid beta peptide reducing agents. Bioorg Med Chem Lett. 2014 Sep 15;24 (18) :4384-4388.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K4695506 1.0 µg DNA
Sox15 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 
E1260Hu 96 Tests
Human IL13RA2/Interleukin-13 receptor subunit alpha-2 ELISA Kit
Sign In for Pricing
View Details 
NBP3-23626-20ug 20 µg
Mouse Monoclonal POGZ Antibody (PCRP-POGZ-1B2)
Sign In for Pricing
View Details bs-3288R-APC 100 µL
Phospho-MYPT1 (Thr853) Polyclonal Antibody, APC Conjugated
Sign In for Pricing
View Details